GlassScriptPhysician profile
Elisha Kang
NPI 1184379596
$7,333.56
in general payments reported to CMS, 2019-2025
22 companies · $52.28 in 2025
The $52.28 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $454 · 2023: $6,114 · 2024: $713 · 2025: $52.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,879.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,107.29 | 2022-2024 | Austedo, Austedo Xr, Uzedy |
| Abbvie INC. | $1,059.70 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $922.47 | 2022-2024 | Spravato, Invega Trinza, Invega |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $623.44 | 2022-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $531.30 | 2022-2023 | Ingrezza |
| Vanda Pharmaceuticals INC. | $480.66 | 2022-2024 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $408.64 | 2023 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $317.94 | 2023 | Rexulti |
| Alkermes, INC. | $315.81 | 2022-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $292.60 | 2022-2023 | Trintellix |
| Corium, LLC | $270.07 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $216.17 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $204.18 | 2022-2023 | Auvelity |
| Noven Therapeutics, LLC | $152.75 | 2023-2024 | Xelstrym, Secuado |
| Almatica Pharma LLC | $101.50 | 2023 | Loreev Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $86.63 | 2023 | Sublocade, Perseris |
| Merck Sharp & Dohme LLC | $60.65 | 2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $55.33 | 2022 | |
| Heartflow, INC. | $45.67 | 2024 | |
| Idorsia Pharmaceuticals US INC | $36.18 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $29.25 | 2023 | Latuda |
| Bausch Health US, LLC | $15.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisha Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.